Abstract Background Pioglitazone (PIO), a thiazolidinediones drug, is a well-known anti-diabetic medicine, but its anti-atherosclerotic effects remain controversial. Thus it is important to investigate the effects of PIO on atherogenesis and the relevant mechanisms. Methods For in vitro studies, primary cultured or AMP-activated protein kinase (AMPK) inhibited splenocytes were treated with oxidized low density lipoprotein (ox-LDL) or ox-LDL plus PIO. Percentage of T helper 17 (Th17) and regulatory T (Treg) cells were determined by flow cytometry. Expression of AMPK, interleukin-17 (IL-17) and forkhead box P3 (FoxP3) were detected by Western blots. For in vivo studies, apolipoprotein E–deficient (apoE−/−) mice fed with western diet were trea...
Pioglitazone (PIO) is a peroxisome proliferator-activated receptor (PPAR)γ agonist insulin-sensitise...
BackgroundThe nuclear receptor peroxisome proliferator-activator gamma (PPARγ) is a useful therapeut...
Rationale: Peroxisome proliferator-activated receptor (PPAR){gamma} agonists attenuate atheroscleros...
Background—Thiazolidinediones (TZDs), which have actions that involve both peroxisome proliferator–a...
Aim: Perivascular adipose tissue (PVAT) is in intimate contact with the vessel wall and extravascula...
Pioglitazone (PIO), a synthetic ligand for peroxisome proliferator activated receptor γ (PPARγ), is ...
ObjectivesThe aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, wi...
Peroxisome proliferator activated receptor γ (PPARγ) has been closely involved in the process of car...
Background: Type 2 diabetes mellitus (T2DM) is commonly associated with both microvascular and macro...
Pioglitazone (pio) has been used as an effective hypoglycemic drug in medicine, however, the effects...
BACKGROUND: Type 2 diabetes mellitus (T2DM) is commonly associated with both microvascular and macro...
ObjectivesOur aim was to investigate if the peroxisome proliferator-activated receptor (PPAR)-γ agon...
AbstractThiazolidinediones (TZDs), potent peroxisome proliferator-activated receptor γ ligands, have...
Objective: Chronic infusion of angiotensin II (AngII) augments development of atherosclerosis and in...
ObjectivesWe sought to determine the antiatherosclerotic properties of pioglitazone using multimetho...
Pioglitazone (PIO) is a peroxisome proliferator-activated receptor (PPAR)γ agonist insulin-sensitise...
BackgroundThe nuclear receptor peroxisome proliferator-activator gamma (PPARγ) is a useful therapeut...
Rationale: Peroxisome proliferator-activated receptor (PPAR){gamma} agonists attenuate atheroscleros...
Background—Thiazolidinediones (TZDs), which have actions that involve both peroxisome proliferator–a...
Aim: Perivascular adipose tissue (PVAT) is in intimate contact with the vessel wall and extravascula...
Pioglitazone (PIO), a synthetic ligand for peroxisome proliferator activated receptor γ (PPARγ), is ...
ObjectivesThe aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, wi...
Peroxisome proliferator activated receptor γ (PPARγ) has been closely involved in the process of car...
Background: Type 2 diabetes mellitus (T2DM) is commonly associated with both microvascular and macro...
Pioglitazone (pio) has been used as an effective hypoglycemic drug in medicine, however, the effects...
BACKGROUND: Type 2 diabetes mellitus (T2DM) is commonly associated with both microvascular and macro...
ObjectivesOur aim was to investigate if the peroxisome proliferator-activated receptor (PPAR)-γ agon...
AbstractThiazolidinediones (TZDs), potent peroxisome proliferator-activated receptor γ ligands, have...
Objective: Chronic infusion of angiotensin II (AngII) augments development of atherosclerosis and in...
ObjectivesWe sought to determine the antiatherosclerotic properties of pioglitazone using multimetho...
Pioglitazone (PIO) is a peroxisome proliferator-activated receptor (PPAR)γ agonist insulin-sensitise...
BackgroundThe nuclear receptor peroxisome proliferator-activator gamma (PPARγ) is a useful therapeut...
Rationale: Peroxisome proliferator-activated receptor (PPAR){gamma} agonists attenuate atheroscleros...